Various forms of cardiovascular disease such as coronary artery disease, arrhythmia (atrial fibrillation and atrial flutter) and heart failure are commonly occurring chronic diseases. It has been estimated that approximately 1.4 million people in Sweden suffer from cardiovascular disease. Such conditions influence the ability of those affected to live a normal life.
Previous studies have shown that 20-40% of people affected by cardiovascular disease also suffer from significant depressive symptoms. Thus, it is not uncommon that people with cardiovascular disease also suffer from depressive symptoms. Furthermore, research has shown that people with cardiovascular disease who at the same time experience depressive symptoms often have poorer wellbeing and more serious health problems than people who suffer from cardiovascular disease alone. One important purpose of this study, thus, is to improve the management and treatment of people with cardiovascular disease and depressive symptoms.
The research project was awarded a grant of more than SEK 3 million in 2015, for the three-year period ending in 2018.
The treatment phase of the study was concluded in the summer of 2018. The data collected are currently being summarised, and information concerning long-term effects collated. In addition, the study participants are being interviewed. It is intended that the data from the study will be presented in the spring of 2019.
Previous studies have shown that 20-40% of people affected by cardiovascular disease also suffer from significant depressive symptoms. Thus, it is not uncommon that people with cardiovascular disease also suffer from depressive symptoms. Furthermore, research has shown that people with cardiovascular disease who at the same time experience depressive symptoms often have poorer wellbeing and more serious health problems than people who suffer from cardiovascular disease alone. One important purpose of this study, thus, is to improve the management and treatment of people with cardiovascular disease and depressive symptoms.
The research project was awarded a grant of more than SEK 3 million in 2015, for the three-year period ending in 2018.
The treatment phase of the study was concluded in the summer of 2018. The data collected are currently being summarised, and information concerning long-term effects collated. In addition, the study participants are being interviewed. It is intended that the data from the study will be presented in the spring of 2019.
